|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.4 SEK | -4.67% |
|
-3.55% | +31.95% |
| 05-08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
| 04-17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Orexo AB (publ) reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was SEK 624.3 million compared to SEK 565 million a year ago. Net loss was SEK 177.6 million compared to SEK 223.5 million a year ago.
Basic loss per share from continuing operations was SEK 5.17 compared to SEK 6.51 a year ago. Diluted loss per share from continuing operations was SEK 5.17 compared to SEK 6.51 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +31.95% | 66.01M | |
| +8.35% | 8.72B | |
| -16.83% | 4.79B | |
| +47.36% | 4.62B | |
| +1.74% | 3.82B | |
| +14.51% | 2.33B | |
| -26.23% | 2.2B | |
| +15.63% | 2.1B | |
| -34.87% | 2.04B | |
| -0.50% | 1.64B |
OREXO AB 
